Loading clinical trials...
Loading clinical trials...
A Phase 1, Single-center, Open-label, Sequential Drug Interaction Study Between AVP-786 (Deuterated [d6] Dextromethorphan Hydrobromide [DM]/Quinidine Sulfate [Q]) and Paroxetine and Between AVP-786 and Duloxetine in Healthy Subjects
Conditions
Interventions
AVP-786
Paroxetine
+1 more
Locations
1
Australia
Nucleus Network
Melbourne, Victoria, Australia
Start Date
January 1, 2014
Primary Completion Date
March 1, 2014
Completion Date
April 1, 2014
Last Updated
February 18, 2022
NCT06682325
NCT07330531
NCT07017335
NCT04487145
NCT04459585
NCT04621253
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions